JP2023520969A5 - - Google Patents

Info

Publication number
JP2023520969A5
JP2023520969A5 JP2022548950A JP2022548950A JP2023520969A5 JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5 JP 2022548950 A JP2022548950 A JP 2022548950A JP 2022548950 A JP2022548950 A JP 2022548950A JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5
Authority
JP
Japan
Prior art keywords
acid sequence
antibody
seq
antibody according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520969A (ja
JP7813234B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025775 external-priority patent/WO2021207072A1/en
Publication of JP2023520969A publication Critical patent/JP2023520969A/ja
Publication of JP2023520969A5 publication Critical patent/JP2023520969A5/ja
Application granted granted Critical
Publication of JP7813234B2 publication Critical patent/JP7813234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548950A 2020-04-07 2021-04-05 抗tmprss6抗体及びその用途 Active JP7813234B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023520969A JP2023520969A (ja) 2023-05-23
JP2023520969A5 true JP2023520969A5 (https=) 2024-04-26
JP7813234B2 JP7813234B2 (ja) 2026-02-12

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548950A Active JP7813234B2 (ja) 2020-04-07 2021-04-05 抗tmprss6抗体及びその用途

Country Status (9)

Country Link
US (3) US12215170B2 (https=)
EP (1) EP4126220A1 (https=)
JP (1) JP7813234B2 (https=)
KR (1) KR20230007368A (https=)
CN (1) CN115243762A (https=)
AU (1) AU2021251087A1 (https=)
CA (1) CA3174339A1 (https=)
TW (1) TW202204422A (https=)
WO (1) WO2021207072A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
CN115243762A (zh) 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
JP2025540726A (ja) * 2022-11-25 2025-12-16 マブウェル・セラピューティクス・インコーポレイテッド 抗tmprss6抗体およびその使用
WO2024211404A2 (en) * 2023-04-04 2024-10-10 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法
HRP20191883T1 (hr) * 2011-11-07 2019-12-27 Ionis Pharmaceuticals, Inc. Modulacija ekspresije tmprss6
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
DE112014005975T5 (de) 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
KR20220107252A (ko) 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4330392A1 (en) 2021-04-26 2024-03-06 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
AU2022265493A1 (en) 2021-04-27 2023-09-21 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders

Similar Documents

Publication Publication Date Title
JP2023520969A5 (https=)
JP2024038003A5 (https=)
JP2020508655A5 (https=)
JP2021530251A5 (https=)
JP2022512132A5 (https=)
JP2010502183A5 (https=)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2018516853A5 (https=)
JP2021520832A5 (https=)
JP2012525829A5 (https=)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
JP2020524510A5 (https=)
JP2023509390A5 (https=)
JP2015511817A5 (https=)
JP2009225799A5 (https=)
JP2018522888A5 (https=)
JP2021530244A5 (https=)
JP2011527899A5 (https=)
JP2025067915A5 (https=)
JP2023540526A5 (https=)
JP2009509538A5 (https=)
JP2019505477A5 (https=)
JP2024512135A5 (https=)
JP2015508056A5 (https=)
JP2024516098A5 (https=)